References
- Barrer RM. 1951. Diffusion in and through solids. London: Cambridge University Press.
- Benowitz NL. 2009. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 49:57–71.
- Boublik T, Fried V, Hala E. 1984. The vapour pressures of pure substances. 2nd Revised ed. Amsterdam: Elsevier.
- Caldwell B, Sumner W, Crane J. 2012. A systematic review of nicotine by inhalation: is there a role for the inhaled route? Nicotine Tob Res. 14(10):1127–1139.
- Crank J. 1975. The mathematics of diffusion. 2nd ed. Oxford, England: Clarendon Press.
- Dahlin KL, Mortberg A, Lastbom L, Ryrfeldt A. 1999. Amitriptyline-induced release of endothelin-1 in isolated perfused and ventilated rat lungs. Pharmacol Toxicol. 85(6):288–293.
- Fagerström K. 2014. Nicotine: pharmacology, toxicity and therapeutic use. J Smok Cessat. 9(2):53–59.
- FDA CDER. 2005. Guidance for industry - estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). [accessed 2019 July] https://www.fda.gov/media/72309/download.
- Fioni A, Selg E, Cenacchi V, Acevedo F, Brogin G, Gerde P, Puccini P. 2018. Investigation of lung pharmacokinetic of the novel PDE4 inhibitor CHF6001 in preclinical models: evaluation of the preciseinhale technology. J Aerosol Med Pulm Drug Deliv. 31(1):61–70.
- Gerde P, Malmlof M, Havsborn L, Sjoberg CO, Ewing P, Eirefelt S, Ekelund K. 2017. DissolvIt: an in vitro method for simulating the dissolution and absorption of inhaled dry powder drugs in the lungs. Assay Drug Dev Technol. 15(2):77–88.
- Gerde P, Scott BR. 2001. A model for absorption of low-volatile toxicants by the airway mucosa. Inhal Toxicol. 13(10):903–929.
- Kroll F, Karlsson JA, Nilsson E, Persson CG, Ryrfeldt A. 1986. Lung mechanics of the guinea-pig isolated perfused lung. Acta Physiol Scand. 128(1):1–8.
- Lunell E, Bergstrom M, Antoni G, Langstrom B, Nordberg A. 1996. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clin Pharmacol Ther. 59(5):593–594.
- US National Library of Medicine. 2018. Substance Name: Nicotine [USP:BAN]. Toxiciology Data Network: U.S. National Library of Medicine; [accessed 2018]. https://chem.nlm.nih.gov/chemidplus/rn/54-11-5.
- Nair AB, Jacob S. 2016. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharma. 7(2):27–31.
- OECD. 2009. Test No. 413: Subchronic Inhalation Toxicity: 90-day Study. OECD Publishing.
- Pankow JF. 2001. A consideration of the role of gas/particle partitioning in the deposition of nicotine and other tobacco smoke compounds in the respiratory tract. Chem Res Toxicol. 14(11):1465–1481.
- Rubow KL, Marple VA, Olin J, McCawley MA. 1987. A personal cascade impactor: design, evaluation and calibration. Am Ind Hyg Assoc J. 48(6):532–538.
- Selg E, Ewing P, Acevedo F, Sjoberg CO, Ryrfeldt A, Gerde P. 2013. Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate. J Aerosol Med Pulm Drug Deliv. 26(4):181–189.
- Velaga SP, Djuris J, Cvijic S, Rozou S, Russo P, Colombo G, Rossi A. 2018. Dry powder inhalers: an overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products. Eur J Pharm Sci. 113:18–28.
- Watanabe K, Nishio T, Mori C, Kihara M, Yamori Y. 1984. Measurement of cardiac output by the thermodilution method in conscious spontaneously hypertensive rats. Jpn Heart J. 25(6):1051–1058.
- Zhang Y, Huo M, Zhou J, Xie S. 2010. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Program Biomed. 99(3):306–314.